Document Type
Perspective
Publication Title
Emory Corp. Governance & Accountability Rev. Perspectives
Publication Date
1-1-2018
Abstract
In response to some of the most egregious abuses of the citizen petition process, pharmaceutical manufacturers who raise concerns via the petition process that relate to their own product's formulation, delivery system, or any other aspect should be estopped from continuing to market and sell their product as is. If a drug manufacturer files a 505(q) petition, the FDA should force the filing manufacturer to comply in regards to their own products with the suggested requirements they make for the generic competition.
First Page
115
Volume
5
Recommended Citation
Eric Evans,
Citizen Petitions: A Process Hijacked by Big Pharma?,
5
Emory Corp. Governance & Accountability Rev. Perspectives
115
(2018).
Available at:
https://scholarlycommons.law.emory.edu/ecgar-perspectives/9